The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The impact of mutation screening on transplant decisions in MDS
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the impact of mutation screening on transplant decisions in myelodysplastic syndromes (MDS). The presence of certain mutations at the time of transplantation are known to predict poor prognosis. Dr Garcia comments that with increasing understanding of disease biology, it is becoming more clear that different mutations must be tackled in different ways and should play a role in decision making. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
